Drug profile · INN
aflibercept-jbvf
YESAFILI
aflibercept-jbvf (YESAFILI) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — aflibercept-jbvf
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
aflibercept-jbvf (YESAFILI) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Placenta growth factor inhibitor
Primary target: Placenta growth factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is aflibercept-jbvf?
aflibercept-jbvf (YESAFILI) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aflibercept-jbvf?
YESAFILI is a marketed brand name for aflibercept-jbvf. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aflibercept-jbvf?
aflibercept-jbvf has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.